Advertisement

Targeting Hormones for Improving Cognition in Major Mood Disorders and Schizophrenia: Thyroid Hormones and Prolactin

Abstract

Cognitive deficits are a core feature of serious mental illnesses such as major depression, bipolar disorder and schizophrenia and are a common cause of functional disability. However, the efficacy of pharmacological interventions for improving the cognitive deficits in these disorders is limited. As pro-cognitive pharmacological treatments are lacking, we aimed to review whether thyroid hormones or drugs that target prolactin may become potential candidates for ‘repurposing’ trials aiming to improve cognition. We conducted a narrative review focused on thyroid hormones and prolactin as potential targets for improving cognition in major mood disorders or schizophrenia. The role of thyroid hormones and prolactin on cognitive processes in non-psychiatric populations was also reviewed. Although clinical trials regarding these hormones are lacking, particularly in patients with schizophrenia, bipolar disorder or major depression, there is evidence from observational studies for the contribution of these hormones to cognitive processes. Patients with bipolar disorder and subclinical hypothyroidism show poorer cognitive function than euthyroid patients. In patients with early psychosis, lower free thyroxine concentrations have been associated with poorer attention whereas increased prolactin levels have been associated with poorer speed of processing. Only two small clinical trials tested the potential pro-cognitive effects of thyroid hormones, with positive findings for triiodothyronine (T3) treatment in patients receiving lithium or electroconvulsive therapy. In sum, thyroid hormones and prolactin might contribute to the cognitive performance of patients with major mood disorders and psychotic disorders. Thyroid hormones and prolactin-lowering drugs (e.g. cabergoline, aripiprazole) are candidate drugs to be tested in repurposing clinical trials aiming to improve the cognitive abilities of patients with major mood disorder and schizophrenia.

This is a preview of subscription content, log in to check access.

Access options

Buy single article

Instant unlimited access to the full article PDF.

US$ 49.95

Price includes VAT for USA

References

  1. 1.

    Vigo D, Thornicroft G, Atun R. Estimating the true global burden of mental illness. Lancet Psychiatry. 2016;3:171–8.

  2. 2.

    Iosifescu DV. The relation between mood, cognition and psychosocial functioning in psychiatric disorders. Eur Neuropsychopharmacol. 2012;22(Suppl 3):S499–504.

  3. 3.

    Lee RSC, Hermens DF, Naismith SL, Lagopoulos J, Jones A, Scott J, et al. Neuropsychological and functional outcomes in recent-onset major depression, bipolar disorder and schizophrenia-spectrum disorders: a longitudinal cohort study. Transl Psychiatry. 2015;5:e555.

  4. 4.

    Penadés R, García-Rizo C, Bioque M, González-Rodríguez A, Cabrera B, Mezquida G, et al. The search for new biomarkers for cognition in schizophrenia. Schizophr Res Cogn. 2015;2:172–8.

  5. 5.

    Soria V, González-Rodríguez A, Huerta-Ramos E, Usall J, Cobo J, Bioque M, et al. Targeting hypothalamic–pituitary–adrenal axis hormones and sex steroids for improving cognition in major mood disorders and schizophrenia: a systematic review and narrative synthesis. Psychoneuroendocrinology. 2018;93:8–19.

  6. 6.

    Jose J, Nandeesha H, Kattimani S, Meiyappan K, Sarkar S, Sivasankar D. Association between prolactin and thyroid hormones with severity of psychopathology and suicide risk in drug free male schizophrenia. Clin Chim Acta. 2015;444:78–80.

  7. 7.

    Schroeder AC, Privalsky ML. Thyroid hormones, T3 and T4, in the brain. Front Endocrinol (Lausanne). 2014;5:40.

  8. 8.

    Bernal J. Thyroid hormones in brain development and function. Endotext [Internet]. 2015.

  9. 9.

    Bradley DJ, Young W, Weinberger C, Young WS 3rd. Differential expression of alpha and beta thyroid hormone receptor genes in rat brain and pituitary. Proc Natl Acad Sci USA. 1989;86:7250–4.

  10. 10.

    Dezonne RS, Lima FRS, Trentin AG, Gomes FC. Thyroid hormone and astroglia: endocrine control of the neural environment. J Neuroendocrinol. 2015;27:435–45.

  11. 11.

    Noda M. Thyroid hormone in the CNS: contribution of neuron–glia interaction. Vitam Horm. 2018;106:313–31.

  12. 12.

    Dallérac G, Rouach N. Astrocytes as new targets to improve cognitive functions. Prog Neurobiol. 2016;144:48–67.

  13. 13.

    Samuels MH. Thyroid disease and cognition. Endocrinol Metab Clin N Am [Internet]. 2014;43:529–43.

  14. 14.

    Zhu DF, Wang ZX, Zhang DR, Pan ZL, He S, Hu XP, et al. fMRI revealed neural substrate for reversible working memory dysfunction in subclinical hypothyroidism. Brain. 2006;129:2923–30.

  15. 15.

    Pasqualetti G, Pagano G, Rengo G, Ferrara N, Monzani F. Subclinical hypothyroidism and cognitive impairment: systematic review and meta-analysis. J Clin Endocrinol Metab. 2015;100:4240–8.

  16. 16.

    Aghili R, Khamseh ME, Malek M, Hadian A, Baradaran HR, Najafi L, et al. Changes of subtests of Wechsler Memory Scale and cognitive function in subjects with subclinical hypothyroidism following treatment with levothyroxine. Arch Med Sci. 2012;8:1096–101.

  17. 17.

    Correia N, Mullally S, Cooke G, Tun TK, Phelan N, Feeney J, et al. Evidence for a specific defect in hippocampal memory in overt and subclinical hypothyroidism. J Clin Endocrinol Metab. 2009;94:3789–97.

  18. 18.

    Kramer CK, Von Mühlen D, Kritz-Silverstein D, Barrett-Connor E. Treated hypothyroidism, cognitive function, and depressed mood in old age: the Rancho Bernardo Study. Eur J Endocrinol. 2009;161:917–21.

  19. 19.

    Siegmund W, Spieker K, Weike AI, Giessmann T, Modess C, Dabers T, et al. Replacement therapy with levothyroxine plus triiodothyronine (bioavailable molar ratio 14:1) is not superior to thyroxine alone to improve well-being and cognitive performance in hypothyroidism. Clin Endocrinol (Oxf). 2004;60:750–7.

  20. 20.

    He X-S, Ma N, Pan Z-L, Wang Z-X, Li N, Zhang X-C, et al. Functional magnetic resource imaging assessment of altered brain function in hypothyroidism during working memory processing. Eur J Endocrinol [Internet]. 2011;164:951–9.

  21. 21.

    Wekking EM, Appelhof BC, Fliers E, Schene AH, Huyser J, Tijssen JGP, et al. Cognitive functioning and well-being in euthyroid patients on thyroxine replacement therapy for primary hypothyroidism. Eur J Endocrinol. 2005;153:747–53.

  22. 22.

    Biondi B, Wartofsky L. Combination treatment with T4 and T3: Toward personalized replacement therapy in hypothyroidism? J Clin Endocrinol Metab. 2012;97:2256–71.

  23. 23.

    Jo S, Fonseca TL, Bocco BMLC, Fernandes GW, McAninch EA, Bolin AP, et al. Type 2 deiodinase polymorphism causes ER stress and hypothyroidism in the brain. J Clin Investig. 2019;129:230–45.

  24. 24.

    Panicker V, Saravanan P, Vaidya B, Evans J, Hattersley AT, Frayling TM, et al. Common variation in the DIO2 gene predicts baseline psychological well-being and response to combination thyroxine plus triiodothyronine therapy in hypothyroid patients. J Clin Endocrinol Metab. 2009;94:1623–9.

  25. 25.

    Duval F, Mokrani MC, Erb A, Gonzalez Lopera F, Alexa C, Proudnikova X, et al. Chronobiological hypothalamic–pituitary–thyroid axis status and antidepressant outcome in major depression. Psychoneuroendocrinology. 2015;59:71–80.

  26. 26.

    Chakrabarti S. Thyroid functions and bipolar affective disorder. J Thyroid Res. 2011;2011:1–13.

  27. 27.

    Barbero JD, Garcia-Parés G, Llorens M, Tost M, Cobo J, Palao D, et al. Thyroglobulin antibodies and risk of readmission at one year in subjects with bipolar disorder. Psychiatry Res. 2014;219:109–13.

  28. 28.

    Cobo J, Giménez-Palop O, Patró E, Pérez M, Bleda F, Barbero JD, et al. Lack of confirmation of thyroid endophenotype in Bipolar Disorder Type I and their first-degree relatives. Psychoneuroendocrinology. 2015;51:351–64.

  29. 29.

    Gyulai L, Bauer M, Bauer MS, García-España F, Cnaan A, Whybrow PC. Thyroid hypofunction in patients with rapid-cycling bipolar disorder after lithium challenge. Biol Psychiatry. 2003;53:899–905.

  30. 30.

    Hickie I, Bennett B, Mitchell P, Wilhelm K, Orlay W. Clinical and subclinical hypothyroidism in patients with chronic and treatment-resistant depression. Aust N Z J Psychiatry. 1996;30:246–52.

  31. 31.

    Berk M, Dandash O, Daglas R, Cotton SM, Allott K, Fornito A, et al. Neuroprotection after a first episode of mania: a randomised controlled maintenance trial comparing the effects of lithium and quetiapine on grey and white matter volume. Transl Psychiatry. 2017;7:e1011.

  32. 32.

    Lazarus JH. The effects of lithium therapy on thyroid and thyrotropin-releasing hormone. Thyroid. 1998;8:909–13.

  33. 33.

    Prohaska ML, Stern RA, Nevels CT, Mason GA, Prange AJJ. The relationship between thyroid status and neuropsychological performance in psychiatric outpatients maintained on lithium. Neuropsychiatry Neuropsychol Behav Neurol. 1996;9:30–4.

  34. 34.

    Martino DJ, Strejilevich SA. Subclinical hypothyroidism and neurocognitive functioning in bipolar disorder. J Psychiatr Res. 2015;61:166–7.

  35. 35.

    Sani G, Perugi G, Tondo L. Treatment of bipolar disorder in a lifetime perspective: is lithium still the best choice? Clin Drug Investig. 2017;37:713–27.

  36. 36.

    Simonetti A, Sani G, Dacquino C, Piras F, De Rossi P, Caltagirone C, et al. Hippocampal subfield volumes in short- and long-term lithium-treated patients with bipolar I disorder. Bipolar Disord. 2016;18:352–62.

  37. 37.

    Prohaska ML, Stern RA, Mason GA, Nevels CT, Prange AJ. Thyroid hormone and lithium-related neuropsychological deficits: a preliminary test of the lithium-thyroid interactive hypothesis. J Int Neuropsychol Soc. 1995;1:134.

  38. 38.

    Stern RA, Nevels CT, Shelhorse ME, Prohaska ML, Mason GA, Prange AJ. Antidepressant and memory effects of combined thyroid hormone treatment and electroconvulsive therapy: preliminary findings. Biol Psychiatry. 1991;30:623–7.

  39. 39.

    Tremont G, Stern RA. Minimizing the cognitive effects of lithium therapy and electroconvulsive therapy using thyroid hormone. Int J Neuropsychopharmacol [Internet]. 2000;3:175–86.

  40. 40.

    Ionescu DF, Rosenbaum JF, Alpert JE. Pharmacological approaches to the challenge of treatment-resistant depression. Dialogues Clin Neurosci. 2015;17:111–26.

  41. 41.

    Joffe RT, Singer W. A comparison of triiodothyronine and thyroxine in the potentiation of tricyclic antidepressants. Psychiatry Res. 1990;32:241–51.

  42. 42.

    Bauer M, Hellweg R, Gräf KJ, Baumgartner A. Treatment of refractory depression with high-dose thyroxine. Neuropsychopharmacology. 1998;18:444–55.

  43. 43.

    Bauer M, Berghöfer A, Bschor T, Baumgartner A, Kiesslinger U, Hellweg R, et al. Supraphysiological doses of L-thyroxine in the maintenance treatment of prophylaxis-resistant affective disorders. Neuropsychopharmacology. 2002;27:620–8.

  44. 44.

    Bauer MS, Whybrow PC. Rapid cycling bipolar affective disorder. II. Treatment of refractory rapid cycling with high-dose levothyroxine: a preliminary study. Arch Gen Psychiatry [Internet]. 1990;47:435–40.

  45. 45.

    Bauer M, London ED, Rasgon N, Berman SM, Frye MA, Altshuler LL, et al. Supraphysiological doses of levothyroxine alter regional cerebral metabolism and improve mood in bipolar depression. Mol Psychiatry. 2005;10:456–69.

  46. 46.

    Bauer M, Berman S, Stamm T, Plotkin M, Adli M, Pilhatsch M, et al. Levothyroxine effects on depressive symptoms and limbic glucose metabolism in bipolar disorder: a randomised, placebo-controlled positron emission tomography study. Mol Psychiatry. 2016;21:229–36.

  47. 47.

    Othman SS, Abdul Kadir K, Hassan J, Hong GK, Singh BB, Raman N. High prevalence of thyroid function test abnormalities in chronic schizophrenia. Aust N Z J Psychiatry [Internet]. 1994;28:620–4.

  48. 48.

    Wysokiński A, Kłoszewska I. Level of thyroid-stimulating hormone (TSH) in patients with acute schizophrenia, unipolar depression or bipolar disorder. Neurochem Res. 2014;39:1245–53.

  49. 49.

    Kiriike N, Izumiya Y, Nishiwaki S, Maeda Y, Nagata T, Kawakita Y. TRH test and DST in schizoaffective mania, mania, and schizophrenia. Biol Psychiatry. 1988;24:415–22.

  50. 50.

    Ichioka S, Terao T, Hoaki N, Matsushita T, Hoaki T. Triiodothyronine may be possibly associated with better cognitive function and less extrapyramidal symptoms in chronic schizophrenia. Prog Neuro-Psychopharmacol Biol Psychiatry. 2012;39:170–4.

  51. 51.

    Barbero JD, Gutiérrez-Zotes A, Montalvo I, Creus M, Cabezas Á, Solé M, et al. Free thyroxine levels are associated with cognitive abilities in subjects with early psychosis. Schizophr Res. 2015;166:37–42.

  52. 52.

    Labad J, Barbero JD, Gutiérrez-Zotes A, Montalvo I, Creus M, Cabezas Á, et al. Free thyroxine levels are associated with cognitive changes in individuals with a first episode of psychosis: a prospective 1-year follow-up study. Schizophr Res. 2016;171:182–6.

  53. 53.

    Jonklaas J, Bianco AC, Bauer AJ, Burman KD, Cappola AR, Celi FS, et al. Guidelines for the treatment of hypothyroidism: prepared by the American Thyroid Association Task Force on thyroid hormone replacement. Thyroid. 2014;24:1670–751.

  54. 54.

    Rosario PW, Calsolari MR. How selective are the new guidelines for treatment of subclinical hypothyroidism for patients with thyrotropin levels at or below 10 mIU/L? Thyroid. 2013;23:562–5.

  55. 55.

    Garber JR, Cobin RH, Gharib H, Hennessey JV, Klein I, Mechanick JI, et al. Clinical practice guidelines for hypothyroidism in adults: cosponsored by the American Association of Clinical Endocrinologists and the American Thyroid Association. Endocr Pract. 2012;18:988–1028.

  56. 56.

    Pearce SHS, Brabant G, Duntas LH, Monzani F, Peeters RP, Razvi S, et al. 2013 ETA guideline: management of subclinical hypothyroidism. Eur Thyroid J. 2013;2:215–28.

  57. 57.

    Bora E, Yücel M, Pantelis C. Cognitive impairment in affective psychoses: a meta-analysis. Schizophr Bull. 2010;36:112–25.

  58. 58.

    Bora E, Yucel M, Pantelis C. Cognitive functioning in schizophrenia, schizoaffective disorder and affective psychoses: meta-analytic study. Br J Psychiatry. 2009;195:475–82.

  59. 59.

    Carta MG, Loviselli A, Hardoy MC, Massa S, Cadeddu M, Sardu C, et al. The link between thyroid autoimmunity (antithyroid peroxidase autoantibodies) with anxiety and mood disorders in the community: a field of interest for public health in the future. BMC Psychiatry. 2004;4:25.

  60. 60.

    Iseme RA, McEvoy M, Kelly B, Agnew L, Attia J, Walker FR. Autoantibodies and depression. Evidence for a causal link? Neurosci Biobehav Rev. 2014;40:62–79.

  61. 61.

    Fountoulakis KN, Iacovides A, Grammaticos P, St. Kaprinis G, Bech P. Thyroid function in clinical subtypes of major depression: an exploratory study. BMC Psychiatry. 2004;4:6.

  62. 62.

    Müller N. Immunological aspects of the treatment of depression and schizophrenia. Dialogues Clin Neurosci. 2017;19:55–63.

  63. 63.

    Halbreich U, Kinon BJ, Gilmore JA, Kahn LS. Elevated prolactin levels in patients with schizophrenia: mechanisms and related adverse effects. Psychoneuroendocrinology. 2003;28(Suppl 1):53–67.

  64. 64.

    Brand JM, Frohn C, Cziupka K, Brockmann C, Kirchner H, Luhm J. Prolactin triggers pro-inflammatory immune responses in peripheral immune cells. Eur Cytokine Netw. 2004;15:99–104.

  65. 65.

    Carvalho-Freitas MIR, Rodrigues-Costa EC, Nasello AG, Palermo-Neto J, Felicio LF. In vitro macrophage activity: Biphasic effect of prolactin and indirect evidence of dopaminergic modulation. Neuroimmunomodulation. 2008;15:131–9.

  66. 66.

    Torner L. Actions of prolactin in the brain: from physiological adaptations to stress and neurogenesis to psychopathology. Front Endocrinol (Lausanne). 2016;7:25.

  67. 67.

    Torner L, Karg S, Blume A, Kandasamy M, Kuhn H-G, Winkler J, et al. Prolactin prevents chronic stress-induced decrease of adult hippocampal neurogenesis and promotes neuronal fate. J Neurosci [Internet]. 2009;29:1826–33.

  68. 68.

    Walker TL, Vukovic J, Koudijs MM, Blackmore DG, Mackay EW, Sykes AM, et al. Prolactin stimulates precursor cells in the adult mouse hippocampus. PLoS One. 2012;7:e44371.

  69. 69.

    Lajud N, Gonzalez-Zapien R, Roque A, Tinajero E, Valdez JJ, Clapp C, et al. Prolactin administration during early postnatal life decreases hippocampal and olfactory bulb neurogenesis and results in depressive-like behavior in adulthood. Horm Behav. 2013;64:781–9.

  70. 70.

    Torner L, Tinajero E, Lajud N, Quintanar-Stéphano A, Olvera-Cortés E. Hyperprolactinemia impairs object recognition without altering spatial learning in male rats. Behav Brain Res. 2013;252:32–9.

  71. 71.

    Brown RSE, Wyatt AK, Herbison RE, Knowles PJ, Ladyman SR, Binart N, et al. Prolactin transport into mouse brain is independent of prolactin receptor. FASEB J. 2016;30:1002–10.

  72. 72.

    Chen J, Ramirez V. Comparison of the effect of prolactin on dopamine release from the rat dorsal and ventral striatum and from the mediobasal hypothalamus superfused in vitro. Eur J Pharmacol. 1988;149:1–8.

  73. 73.

    Perkins N, Westfall T. The effect of prolactin on dopamine release from rat striatum and medial basal hypothalamus. Neuroscience. 1978;3:59–63.

  74. 74.

    Ramirez V. Hormones and striatal dopaminergic activity: a novel neuroendocrine model. In: Bhatnagar A, editor. The anterior pituitary gland. New York: Raven Press; 1983.

  75. 75.

    Cabrera-Reyes EA, Limón-Morales O, Rivero-Segura NA, Camacho-Arroyo I, Cerbón M. Prolactin function and putative expression in the brain. Endocrine. 2017;57:199–213.

  76. 76.

    Henry JF, Sherwin BB. Hormones and cognitive functioning during late pregnancy and postpartum: a longitudinal study. Behav Neurosci. 2011;126:73–85.

  77. 77.

    Farrar D, Tuffnell D, Neill J, Scally A, Marshall K. Assessment of cognitive function across pregnancy using CANTAB: a longitudinal study. Brain Cogn. 2014;84:76–84.

  78. 78.

    Fonda SJ, Bertrand R, O’Donnell A, Longcope C, McKinlay JB. Age, hormones, and cognitive functioning among middle-aged and elderly men: cross-sectional evidence from the Massachusetts Male Aging Study. J Gerontol A Biol Sci Med Sci. 2005;60:385–90.

  79. 79.

    Castanho TC, Moreira PS, Portugal-Nunes C, Novais A, Costa PS, Palha JA, et al. The role of sex and sex-related hormones in cognition, mood and well-being in older men and women. Biol Psychol. 2014;103:158–66.

  80. 80.

    Bala A, Lojek E, Marchel A. Cognitive functioning of patients with a PRL-secreting pituitary adenoma: a preliminary report. Neurology. 2016;86:731–4.

  81. 81.

    Montalvo I, Llorens M, Caparrós L, Pamias M, Torralbas J, Giménez-Palop O, et al. Improvement in cognitive abilities following cabergoline treatment in patients with a prolactin-secreting pituitary adenoma. Int Clin Psychopharmacol. 2018;33:98–102.

  82. 82.

    Yao S, Song J, Gao J, Lin P, Yang M, Zahid KR, et al. Cognitive function and serum hormone levels are associated with gray matter volume decline in female patients with prolactinomas. Front Neurol. 2018;8:742.

  83. 83.

    Garcia-Rizo C, Fernandez-Egea E, Oliveira C, Justicia A, Parellada E, Bernardo M, et al. Prolactin concentrations in newly diagnosed, antipsychotic-naïve patients with nonaffective psychosis. Schizophr Res. 2012;134:16–9.

  84. 84.

    Riecher-Rössler A, Rybakowski JK, Pflueger MO, Beyrau R, Kahn RS, Malik P, et al. Hyperprolactinemia in antipsychotic-naive patients with first-episode psychosis. Psychol Med. 2013;43:2571–82.

  85. 85.

    Gonzalez-Blanco L, Greenhalgh AMD, Garcia-Rizo C, Fernandez-Egea E, Miller BJ, Kirkpatrick B. Prolactin concentrations in antipsychotic-naive patients with schizophrenia and related disorders: a meta-analysis. Schizophr Res. 2016;174:156–60.

  86. 86.

    Lennartsson AK, Jonsdottir IH. Prolactin in response to acute psychosocial stress in healthy men and women. Psychoneuroendocrinology. 2011;36:1530–9.

  87. 87.

    Ittig S, Studerus E, Heitz U, Menghini-Müller S, Beck K, Egloff L, et al. Sex differences in prolactin levels in emerging psychosis: Indication for enhanced stress reactivity in women. Schizophr Res. 2017;189:111–6.

  88. 88.

    Lally J, Ajnakina O, Stubbs B, Williams HR, Colizzi M, Carra E, et al. Hyperprolactinaemia in first episode psychosis—a longitudinal assessment. Schizophr Res. 2017;189:117–25.

  89. 89.

    Labad J. The role of cortisol and prolactin in the pathogenesis and clinical expression of psychotic disorders. Psychoneuroendocrinology. 2019;102:24–36.

  90. 90.

    Moore L, Kyaw M, Vercammen A, Lenroot R, Kulkarni J, Curtis J, et al. Serum testosterone levels are related to cognitive function in men with schizophrenia. Psychoneuroendocrinology. 2013;38:1717–28.

  91. 91.

    Bratek A, Koźmin-Burzyńska A, Krysta K, Cierpka-Wiszniewska K, Krupka-Matuszczyk I. Effects of hormones on cognition in schizophrenic male patients—preliminary results. Psychiatr Danub. 2015;27:S261–5.

  92. 92.

    Montalvo I, Gutiérrez-Zotes A, Creus M, Monseny R, Ortega L, Franch J, et al. Increased prolactin levels are associated with impaired processing speed in subjects with early psychosis. PLoS One. 2014;9:e89428.

  93. 93.

    Montalvo I, Nadal R, Armario A, Gutiérrez-Zotes A, Creus M, Cabezas Á, et al. Sex differences in the relationship between prolactin levels and impaired processing speed in early psychosis. Aust N Z J Psychiatry. 2018;52:585–95.

  94. 94.

    Fariello RG. Pharmacodynamic and pharmacokinetic features of cabergoline. Rationale for use in Parkinson’s disease. Drugs. 1998;55(Suppl 1):10–6.

  95. 95.

    Benedetti MS, Dostert P, Barone D, Efthymiopoulos C, Peretti G, Roncucci R. In vivo interaction of cabergoline with rat brain dopamine receptors labelled with [3H]N-n-propylnorapomorphine. Eur J Pharmacol. 1990;187:399–408.

  96. 96.

    Van Holstein M, Aarts E, Van Der Schaaf ME, Geurts DEM, Verkes RJ, Franke B, et al. Human cognitive flexibility depends on dopamine D2 receptor signaling. Psychopharmacology (Berl). 2011;218:567–78.

  97. 97.

    Chang SC, Chen CH, Lu ML. Cabergoline-induced psychotic exacerbation in schizophrenic patients. Gen Hosp Psychiatry. 2008;30:378–80.

  98. 98.

    Kalkavoura C, Michopoulos I, Arvanitakis P, Theodoropoulou P, Dimopoulou K, Tzebelikos E, et al. Effects of cabergoline on hyperprolactinemia, psychopathology, and sexual functioning in schizophrenic patients. Exp Clin Psychopharmacol. 2013;21:332–41.

  99. 99.

    Coronas R, Cobo J, Gimenez-Palop O, Ortega E, Marquez M. Safety of cabergoline in the management of pituitary prolactin-induced symptoms with patients treated with atypical neuroleptics. Curr Drug Saf. 2012;7:92–8.

  100. 100.

    Centorrino F, Fogarty KV, Cimbolli P, Salvatore P, Thompson TA, Sani G, et al. Aripiprazole: initial clinical experience with 142 hospitalized psychiatric patients. J Psychiatr Pract. 2005;11:241–7.

  101. 101.

    Chen JX, Su YA, Bian QT, Wei LH, Zhang RZ, Liu YH, et al. Adjunctive aripiprazole in the treatment of risperidone-induced hyperprolactinemia: a randomised, double-blind, placebo-controlled, dose-response study. Psychoneuroendocrinology. 2015;58:130–40.

  102. 102.

    Lee BJ, Lee SJ, Kim MK, Lee JG, Park SW, Kim GM, et al. Effect of aripiprazole on cognitive function and hyperprolactinemia in patients with schizophrenia treated with risperidone. Clin Psychopharmacol Neurosci. 2013;11:60–6.

  103. 103.

    Schlagenhauf F, Dinges M, Beck A, Wüstenberg T, Friedel E, Dembler T, et al. Switching schizophrenia patients from typical neuroleptics to aripiprazole: effects on working memory dependent functional activation. Schizophr Res. 2010;118:189–200.

  104. 104.

    Bodnar M, Malla AK, Makowski C, Chakravarty MM, Joober R, Lepage M. The effect of second-generation antipsychotics on hippocampal volume in first episode of psychosis: longitudinal study. Br J Psychiatry Open. 2016;2:139–46.

Download references

Acknowledgements

PNECAT Group: Pilar Álvarez, Juan David Barbero, Miquel Bioque, Jesús Cobo, Núria del Cacho, Clemente García-Rizo, Javier Labad, Ana Martín-Blanco, José Antonio Monreal, Itziar Montalvo, Maria Portella, Eva Real, Elena Rubio, Virginia Soria, Judith Usall. The idea of conducting this review originated at meetings of the Psychoneuroendocrinology Workgroup from the Catalan Society of Psychiatry (PNECAT Group). We are thankful to all of the members of the PNECAT group.

Author information

Correspondence to Javier Labad.

Ethics declarations

Conflict of interest

JL, CGR and MB have received honoraria for lectures or advisory boards from Janssen, Otsuka and Lundbeck. VS has served as consultant or continuing medical education (CME) speaker for Servier, Rovi, Lundbeck, Exeltis, Otsuka, Pfizer, Juste. The rest of the authors have no conflicts of interest to declare.

Funding

This review was supported in part by a grant from the Carlos III Health Institute through the Ministry of Economy and Competitiveness (PI15/01386), the European Regional Development Fund (ERDF) “A way to build Europe”. Javier Labad received an Intensification of the Research Activity Grant (SLT006/17/00012) by the Health Department of the Generalitat de Catalunya.

Additional information

The members of PNECAT Group are listed in “Acknowledgements”.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Tost, M., Monreal, J.A., Armario, A. et al. Targeting Hormones for Improving Cognition in Major Mood Disorders and Schizophrenia: Thyroid Hormones and Prolactin. Clin Drug Investig 40, 1–14 (2020) doi:10.1007/s40261-019-00854-w

Download citation